Eli Lilly to Use Dexcom's Continuous Glucose Monitoring Devices
December 16 2019 - 7:27AM
Dow Jones News
By Dave Sebastian
Eli Lilly & Co. (LLY) said it has struck an agreement with
DexCom Inc. (DXCM) to use Dexcom products in Lilly's currently
developed personalized diabetes management system.
Under the non-exclusive agreement, Lilly said Monday it would
use Dexcom's continuous glucose monitoring devices in both the pen-
and pump-based platforms of the system.
The pen-based platform aims to integrate personalized data from
a prefiled, disposable insulin pen with data from glucose-sensing
technologies into a compatible software application, Lilly
said.
Lilly said the pump-based platform is a hybrid-closed-loop
system that would automate insulin dosing by integrating an insulin
pump, continuous glucose monitor and a handheld controller or
smartphone application that controls the system.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
December 16, 2019 07:12 ET (12:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2023 to Sep 2024